StreetInsider.com News Articles

Axogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026

Wed, 14 Oct 2026 07:00:00 -0400

ALACHUA, Fla. and TAMPA, Fla., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will release financial results for the third quarter of 2026 on Wednesday, October 28, 2026. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release.

Investors interested in participating in the conference call by phone may dial toll-free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. A live webcast, an

Axogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026

Wed, 14 Oct 2026 07:00:00 -0400

Investors interested in participating in the conference call by phone may dial toll-free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. A live webcast, an

BofA Securities Starts AxoGen, Inc. (AXGN) at Buy

Mon, 12 Oct 2026 06:15:04 -0400

(Updated - October 12, 2026 6:15 AM EDT)

BofA Securities analyst Travis Steed initiates coverage on AxoGen, Inc. (NASDAQ: AXGN) with a Buy rating and a price target of $52.00.

The analyst comments "We are initiating coverage on Axogen (AXGN) with a Buy rating and $52 PO (8x EV/CY2027E Sales). Axogen is the market leader in peripheral nerve repair as the only company offering a nerve allograft, Avance, and a comprehensive nerve repair portfolio. BLA approval for Avance in December 2025 strengthened Axogen’s competitive moat and is unlocking broader coverage. We see reasons to believe Axogen can sustain high teens to 20%

BofA Securities Starts AxoGen, Inc. (AXGN) at Buy

Mon, 12 Oct 2026 06:15:04 -0400

(Updated - October 12, 2026 6:15 AM EDT)

BofA Securities analyst Travis Steed initiates coverage on AxoGen, Inc. (NASDAQ: AXGN) with a Buy rating and a price target of $52.00.

BofA Securities Starts AxoGen, Inc. (AXGN) at Buy

Mon, 12 Oct 2026 06:15:04 -0400

(Updated - October 12, 2026 6:15 AM EDT)

BofA Securities analyst Travis Steed initiates coverage on AxoGen, Inc. (NASDAQ: AXGN) with a Buy rating and a price target of $52.00.

BofA Securities Starts AxoGen, Inc. (AXGN) at Buy

Mon, 12 Oct 2026 06:15:04 -0400

(Updated - October 12, 2026 6:15 AM EDT)

BofA Securities analyst Travis Steed initiates coverage on AxoGen, Inc. (NASDAQ: AXGN) with a Buy rating and a price target of $52.00.

Barclays Starts AxoGen, Inc. (AXGN) at Overweight

Tue, 06 Oct 2026 16:25:37 -0400

Barclays initiates coverage on AxoGen, Inc. (NASDAQ: AXGN) with a Overweight rating and a price target of $55.00.

For an analyst ratings summary and ratings history on AxoGen, Inc. click here. For more ratings news on AxoGen, Inc. click here.

Shares of AxoGen, Inc. closed at $37.22 yesterday.

Wound Care Stocks Are Posting Double-Digit Growth. Here’s Why.

Tue, 06 Oct 2026 09:06:00 -0400

RENO, Nev., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Wall Street Investor News Commentary - The global advanced wound care market is valued at $13.37 billion in 2025 and is projected to reach $19.32 billion by 2030, a compound annual growth rate of 7.6%, according to MarketsandMarkets. The firm points to chronic disease, an aging population and traumatic injuries as the main drivers, noting that diabetic foot ulcers affect roughly a quarter of patients with diabetes and are a leading cause of hospitalization. Active Companies from around the markets with current developments this week include:

Wound Care Stocks Are Posting Double-Digit Growth. Here’s Why.

Tue, 06 Oct 2026 09:06:00 -0400

RENO, Nev., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Wall Street Investor News Commentary - The global advanced wound care market is valued at $13.37 billion in 2025 and is projected to reach $19.32 billion by 2030, a compound annual growth rate of 7.6%, according to MarketsandMarkets. The firm points to chronic disease, an aging population and traumatic injuries as the main drivers, noting that diabetic foot ulcers affect roughly a quarter of patients with diabetes and are a leading cause of hospitalization. Active Companies from around the markets with current developments this week include:

Wound Care Stocks Are Posting Double-Digit Growth. Here’s Why.

Tue, 06 Oct 2026 09:06:00 -0400

RENO, Nev., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Wall Street Investor News Commentary - The global advanced wound care market is valued at $13.37 billion in 2025 and is projected to reach $19.32 billion by 2030, a compound annual growth rate of 7.6%, according to MarketsandMarkets. The firm points to chronic disease, an aging population and traumatic injuries as the main drivers, noting that diabetic foot ulcers affect roughly a quarter of patients with diabetes and are a leading cause of hospitalization. Active Companies from around the markets with current developments this week include:

Wound Care Stocks Are Posting Double-Digit Growth. Here’s Why.

Tue, 06 Oct 2026 09:06:00 -0400

RENO, Nev., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Wall Street Investor News Commentary - The global advanced wound care market is valued at $13.37 billion in 2025 and is projected to reach $19.32 billion by 2030, a compound annual growth rate of 7.6%, according to MarketsandMarkets. The firm points to chronic disease, an aging population and traumatic injuries as the main drivers, noting that diabetic foot ulcers affect roughly a quarter of patients with diabetes and are a leading cause of hospitalization. Active Companies from around the markets with current developments this week include:

Wound Care Stocks Are Posting Double-Digit Growth. Here’s Why.

Tue, 06 Oct 2026 09:06:00 -0400

RENO, Nev., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Wall Street Investor News Commentary - The global advanced wound care market is valued at $13.37 billion in 2025 and is projected to reach $19.32 billion by 2030, a compound annual growth rate of 7.6%, according to MarketsandMarkets. The firm points to chronic disease, an aging population and traumatic injuries as the main drivers, noting that diabetic foot ulcers affect roughly a quarter of patients with diabetes and are a leading cause of hospitalization. Active Companies from around the markets with current developments this week include:

Wound Care Stocks Are Posting Double-Digit Growth. Here’s Why.

Tue, 06 Oct 2026 09:06:00 -0400

RENO, Nev., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Wall Street Investor News Commentary - The global advanced wound care market is valued at $13.37 billion in 2025 and is projected to reach $19.32 billion by 2030, a compound annual growth rate of 7.6%, according to MarketsandMarkets. The firm points to chronic disease, an aging population and traumatic injuries as the main drivers, noting that diabetic foot ulcers affect roughly a quarter of patients with diabetes and are a leading cause of hospitalization. Active Companies from around the markets with current developments this week include:

Wound Care Stocks Are Posting Double-Digit Growth. Here’s Why.

Tue, 06 Oct 2026 09:06:00 -0400

RENO, Nev., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Wall Street Investor News Commentary - The global advanced wound care market is valued at $13.37 billion in 2025 and is projected to reach $19.32 billion by 2030, a compound annual growth rate of 7.6%, according to MarketsandMarkets. The firm points to chronic disease, an aging population and traumatic injuries as the main drivers, noting that diabetic foot ulcers affect roughly a quarter of patients with diabetes and are a leading cause of hospitalization. Active Companies from around the markets with current developments this week include:

Wound Care Stocks Are Posting Double-Digit Growth. Here’s Why.

Tue, 06 Oct 2026 09:06:00 -0400

RENO, Nev., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Wall Street Investor News Commentary - The global advanced wound care market is valued at $13.37 billion in 2025 and is projected to reach $19.32 billion by 2030, a compound annual growth rate of 7.6%, according to MarketsandMarkets. The firm points to chronic disease, an aging population and traumatic injuries as the main drivers, noting that diabetic foot ulcers affect roughly a quarter of patients with diabetes and are a leading cause of hospitalization. Active Companies from around the markets with current developments this week include:

Wound Care Stocks Are Posting Double-Digit Growth. Here’s Why.

Tue, 06 Oct 2026 09:06:00 -0400

RENO, Nev., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Wall Street Investor News Commentary - The global advanced wound care market is valued at $13.37 billion in 2025 and is projected to reach $19.32 billion by 2030, a compound annual growth rate of 7.6%, according to MarketsandMarkets. The firm points to chronic disease, an aging population and traumatic injuries as the main drivers, noting that diabetic foot ulcers affect roughly a quarter of patients with diabetes and are a leading cause of hospitalization. Active Companies from around the markets with current developments this week include:

Wound Care Stocks Are Posting Double-Digit Growth. Here’s Why.

Tue, 06 Oct 2026 09:06:00 -0400

RENO, Nev., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Wall Street Investor News Commentary - The global advanced wound care market is valued at $13.37 billion in 2025 and is projected to reach $19.32 billion by 2030, a compound annual growth rate of 7.6%, according to MarketsandMarkets. The firm points to chronic disease, an aging population and traumatic injuries as the main drivers, noting that diabetic foot ulcers affect roughly a quarter of patients with diabetes and are a leading cause of hospitalization. Active Companies from around the markets with current developments this week include:

Form SCHEDULE 13G Axogen, Inc. Filed by: Divisadero Street Capital Management, LP

Fri, 02 Oct 2026 17:36:00 -0400
si-local-file:///var/storage/secattach/20261002/27143725.html

Form 8-K Axogen, Inc. For: Oct 01

Thu, 01 Oct 2026 17:25:00 -0400
si-local-file:///var/storage/secattach/20261001/27137330.html

Axogen acquires BioCircuit, adding sutureless nerve repair device

Thu, 01 Oct 2026 17:19:38 -0400

Axogen, Inc. (Nasdaq: AXGN) has completed its acquisition of privately held BioCircuit Technologies, Inc., gaining ownership of NerveTape™, a device that BioCircuit claims is the first FDA-cleared sutureless option for repairing transected peripheral nerves.

Axogen expects BioCircuit to contribute approximately $6 million to fourth-quarter 2026 revenue and approximately $34 million to full-year 2027 revenue. These figures were not included in Axogen's previously issued full-year 2026 guidance of at least 24% revenue growth. The company said it continues to expect a gross margin of at least 73% and to be free cash flow positive for full-year 2026.

BioCircuit, based in Atlanta, Georgia, develops

Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair

Thu, 01 Oct 2026 17:19:00 -0400

ALACHUA, Fla. and TAMPA, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (“Axogen” or the “Company”) (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it has completed its previously announced acquisition of BioCircuit Technologies, Inc. (“BioCircuit”), a privately held medical device company and developer of NerveTape™.

“This is a significant day for Axogen and the surgeons and patients we serve,” said Michael Dale, President and Chief Executive Officer of Axogen. “NerveTape represents a new standard of care as the first

Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair

Thu, 01 Oct 2026 17:19:00 -0400

ALACHUA, Fla. and TAMPA, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (“Axogen” or the “Company”) (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it has completed its previously announced acquisition of BioCircuit Technologies, Inc. (“BioCircuit”), a privately held medical device company and developer of NerveTape™.

“This is a significant day for Axogen and the surgeons and patients we serve,” said Michael Dale, President and Chief Executive Officer of Axogen. “NerveTape represents a new standard of care as the first

AxoGen, Inc. (AXGN) PT Lowered to $53 at Truist Securities

Thu, 01 Oct 2026 05:23:39 -0400

Truist Securities analyst Ravi Misra lowered the price target on AxoGen, Inc. (NASDAQ: AXGN) to $53.00 (from $60.00) while maintaining a Buy rating.
The analyst comments "Following the 9/10 BioCircuit acquisition announcement, we reached out to a handful of surgeons (n=5) and asked how Nerve Tape fits into their nerve repair workflows. Feedback around the technology was +ive, and even after contemplating cannibalization, we expect forecasts to rebase higher post-close. Our diligence suggests Axoguard Connector, in non-gap repair cases, is most exposed to substitution risk (we provide a framework via hypothetical PF below). We continue to believe AXGN can deliver 20%+

AxoGen, Inc. (AXGN) PT Lowered to $53 at Truist Securities

Thu, 01 Oct 2026 05:23:39 -0400

Truist Securities analyst Ravi Misra lowered the price target on AxoGen, Inc. (NASDAQ: AXGN) to $53.00 (from $60.00) while maintaining a Buy rating.
The analyst comments "Following the 9/10 BioCircuit acquisition announcement, we reached out to a handful of surgeons (n=5) and asked how Nerve Tape fits into their nerve repair workflows. Feedback around the technology was +ive, and even after contemplating cannibalization, we expect forecasts to rebase higher post-close. Our diligence suggests Axoguard Connector, in non-gap repair cases, is most exposed to substitution risk (we provide a framework via hypothetical PF below). We continue to believe AXGN can deliver 20%+

Truist Securities Reiterates Buy Rating on AxoGen, Inc. (AXGN)

Tue, 29 Sep 2026 05:06:27 -0400

Truist Securities analyst Ravi Misra reiterated a Buy rating and $60.00 price target on AxoGen, Inc. (NASDAQ: AXGN).
The analyst comments "This afternoon (9/28) Aetna (CVS, Buy, MacDonald) updated its coverage policy for Nerve Grafting [LINK] expanding coverage of Avance. The updated label notes "Nerve allograft (e.g., Avance) is considered medically necessary for repair of short-to-medium sensory nerve gaps (≤30 mm) in the upper extremity." We view the policy update as a positive development, as it now provides coverage from a payer that had previously considered Avance to be investigational (Avance was also the only nerve graft technology to receive specific